BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 30489424)

  • 1. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
    Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
    Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
    Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
    Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
    Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
    Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
    Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
    Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
    Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
    Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
    Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
    [No Abstract]   [Full Text] [Related]  

  • 10. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
    Archer DF; Bernick BA; Mirkin S
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
    [No Abstract]   [Full Text] [Related]  

  • 11. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
    Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
    Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
    Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
    Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.
    Caan B; LaCroix AZ; Joffe H; Guthrie KA; Larson JC; Carpenter JS; Cohen LS; Freeman EW; Manson JE; Newton K; Reed S; Rexrode K; Shifren J; Sternfeld B; Ensrud K
    Menopause; 2015 Jun; 22(6):607-15. PubMed ID: 25405571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
    Woodis CB; Ghassemi E; McLendon AN
    Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial.
    Diem SJ; Guthrie KA; Mitchell CM; Reed SD; Larson JC; Ensrud KE; LaCroix AZ
    Menopause; 2018 Oct; 25(10):1086-1093. PubMed ID: 29738424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
    Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
    Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
    Cintron D; Lahr BD; Bailey KR; Santoro N; Lloyd R; Manson JE; Neal-Perry G; Pal L; Taylor HS; Wharton W; Naftolin F; Harman SM; Miller VM
    Menopause; 2018 Feb; 25(2):145-153. PubMed ID: 28832429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.